Author’s response to reviews

Title: Transient symptomatic hyperglycaemia secondary to inhaled fluticasone propionate in a young child: a case report

Authors:

Susanna Esposito (Susanna.Esposito@unimi.it)
Mara Lelii (mara.lelii87@gmail.com)
Nicola Principi (nicola.principi@unimi.it)

Version: 1 Date: 07 Dec 2015

Author’s response to reviews:

Editor
BMC Pulmonary Medicine
Milan, 7 December 2015

Dear Editor,

Thank you for considering our manuscript PULM-D-15-00125 entitled "Transient symptomatic hyperglycaemia secondary to inhaled fluticasone propionate in a young child", which we submit for publication as Case Report in BMC Pulmonary Medicine.

Please find attached the revised manuscript and our replies to Editor’s comments and recommendations. The authors, all of whom contributed significantly to the manuscript and declare that they have no potential conflict of interest, have seen and approved the final version of the manuscript.

We declare that the text has been reviewed by a native English speaker with appropriate knowledge of the subject matter. We hope that you will now find the paper suitable for publication in BMC Pulmonary Medicine.

Yours faithfully,

Susanna Esposito, MD
Pediatric Highly Intensive Care Unit
Department of Pathophysiology and Transplantation,
Reviewer 1

Thank you very much for the appreciation of our manuscript. We have modified it as suggested.

1. We clarified that due to the presence of glycosuria, blood alkalosis and clinical symptoms, the hypothesis is that in the month prior to admission the patient’s blood glucose levels were even higher than those detected by us at admission in the Emergency Room (p. 7).

2. Previous studies on ICSs safety has been discussed (p. 6) and appropriate references have been added (pp. 9 and 10).

3. The conclusions have been modified in the Abstract (p. 3) and the Discussion (p. 7).

4. Further details on the clinical case have been shown and discussed (pp. 5, 6 and 11).

5. The term “hyperglycaemia” is used in the Title (p. 1).

Reviewer 2

Thank you very much for your comments. We have modified the manuscript accordingly.

1. It has been clarified that due to its low systemic bioavailability FP has been associated with a lower rate of adverse reactions in comparison to other ICSs including budesonide (p. 2). The study published by Aagaard and Hansen has been mentioned and included among the references (pp. 4 and 9).

2. It has been added that oral corticosteroids were administered several months before FP initiation (pp. 5 and 11).

3. It has been discussed that although the parents confirmed that FP was administered according to recommendations, the reported level of compliance of parents has a very low accuracy (p. 11).
Editorial requests

Thank you very much for the appreciation of our manuscript. Our paper is already in line with all your requirements.